Linezolid: A new antibiotic for newborns and children?

被引:4
作者
Cuzzolin, L.
Fanos, V.
机构
[1] Univ Cagliari, Neonatal Pathol & Intens Care Unit, I-09124 Cagliari, Italy
[2] Univ Verona, Dept Med & Publ Hlth, Pharmacol Sect, I-37100 Verona, Italy
关键词
linezolid; pediatrics; newborns; Gram-positive pathogens; Staphylococcus aureus;
D O I
10.1179/joc.2006.18.6.573
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Staphylococcus aureus remains one of the most common and troublesome microorganisms causing disease in humans, despite the development of effective antibiotics. Linezolid is a member of a new class of synthetic antibiotics called oxazolidinones, introduced into therapy due to the increasing resistance of Gram-positive pathogens to traditional antibiotics. Information about the pharmacokinetics and tolerability profile of linezolid in the pediatric population mostly derive from adult studies and especially in the neonatal field relatively few data are available. Here we summarize linezolid's characteristics and report data available in the literature regarding linezolid use in newborns and children. For this purpose, a Medline search was performed between 1990 and 2006 involving the term "linezolid" combined with the terms "newborn", "infant", "child", "pediatrics". Additional information was obtained from Reactions Weekly (TM).
引用
收藏
页码:573 / 581
页数:9
相关论文
共 57 条
  • [21] Linezolid for the treatment of children with bacteremia or nosocomial pneumonia caused by resistant Gram-positive bacterial pathogens
    Jantausch, BA
    Deville, J
    Adler, S
    Morfin, MR
    Lopez, P
    Edge-Padbury, B
    Naberhuis-Stehouwer, S
    Bruss, JB
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (09) : S164 - S171
  • [22] Linezolid pharmacokinetics in pediatric patients: an overview
    Jungbluth, GL
    Welshman, IR
    Hopkins, NK
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (09) : S153 - S157
  • [23] Linezolid versus vancomycin for treatment of resistant Gram-positive infections in children
    Kaplan, SL
    Deville, JG
    Yogev, R
    Morfin, MR
    Wu, E
    Adler, S
    Edge-Padbury, B
    Naberhuis-Stehouwer, S
    Bruss, JB
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2003, 22 (08) : 677 - 685
  • [24] Linezolid for the treatment of community-acquired pneumonia in hospitalized children
    Kaplan, SL
    Patterson, L
    Edwards, KM
    Azimi, PH
    Bradley, JS
    Blumer, JL
    Tan, TQ
    Lobeck, FG
    Anderson, DC
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2001, 20 (05) : 488 - 494
  • [25] Impact of ontogeny on linezolid disposition in neonates and infants
    Kearns, GL
    Jungbluth, GL
    Abdel-Rahman, SM
    Hopkins, NK
    Welshman, IR
    Grzebyk, RP
    Bruss, JB
    van den Anker, JN
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (05) : 413 - 422
  • [26] Single dose pharmacokinetics of linezolid in infants and children
    Kearns, GL
    Abdel-Rahman, SM
    Blumer, JL
    Reed, MD
    James, LP
    Jacobs, RF
    Welshman, IR
    Jungbluth, GL
    Stalker, DJ
    [J]. PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (12) : 1178 - 1184
  • [27] KINAN A, 2002, CLIN INFECT DIS, V34, P695
  • [28] Resistance mutations in 23 S rRNA identify the site of action of the protein synthesis inhibitor linezolid in the ribosomal peptidyl transferase center
    Kloss, P
    Xiong, LQ
    Shinabarger, DL
    Mankin, AS
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 1999, 294 (01) : 93 - 101
  • [29] Hematologic effects of antimicrobials: Focus on the oxazolidinone linezolid
    Kuter, DJ
    Tillotson, GS
    [J]. PHARMACOTHERAPY, 2001, 21 (08): : 1010 - 1013
  • [30] Staphylococcal skin infections in children: Rational drug therapy recommendations
    Ladhani S.
    Garbash M.
    [J]. Pediatric Drugs, 2005, 7 (2) : 77 - 102